Cancer Care

New Collaborative Advance Care Planning Program for Patients with Cancer Enhances Quality while Mitigating Costs

J. Russell Hoverman, MD, PhD

September 2013, Vol 4, No 7 - Cancer Care

The cancer care landscape is rapidly evolving, in light of promising new therapies, as well as changing reimbursement strategies in response to the healthcare reform. With the cost of some cancer drugs exceeding $100,000 annually, and with patients living longer, cancer care consumes a large portion of healthcare dollars. [ Read More ]

Screening for Pancreatic Cancer Is Effective, Has Value— at Least in High-Risk Individuals

Caroline Helwick

August 2011, Vol 2, No 5 - Cancer Care

Ongoing efforts to screen asymptomatic persons for pancreatic cancer have been unsuccessful, but targeting persons at high risk for the disease appears to be clinically effective as well as cost-effective.

Researchers have combined the use of a serum biomarker, CA 19-9, and endoscopic ultrasonography to create a screening protocol for persons at risk for the malignancy on the basis of family history and age and reported their results in the July issue of Gastro - intestinal Endoscopy (Zubarik R, et al. Gastrointest Endosc. 2011;74:87-95).

[ Read More ]

The Role of Molecular Diagnostics in Cancer Treatment

Wayne Kuznar

July 2011, Vol 2, No 4 - Cancer Care

Philadelphia, PA—The field of oncology stands to benefit greatly from molecular diagnostic trends, according to Jane F. Barlow, MD, MPH, MBA, Vice President, Clinical Innovation, Medco Health Solutions, who offered a pharmacy benefit manager’s (PBM) perspective of the role of diagnostics, including the use of companion tests in drug development. These companion tests will represent another potential expenditure and coverage decision for PBM companies. [ Read More ]